Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Sofosbuvir and velpatasvir for the treatment of hepatitis C.

Expert review of gastroenterology & hepatology - 1 Jun 2017

Jackson Whitney E, Everson Gregory T

Abstract excerpt

INTRODUCTION: Direct acting antivirals are revolutionizing the treatment of chronic hepatitis C. Specifically, the combination therapy sofosbuvir and velpatasvir offers a pangenotypic regimen with high sustained viral response (SVR). Areas covered: Reviewed here are the clinical trials that led to the FDA approval of sofosbuvir and velpatasvir combination therapy, the adverse events during registration trials,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carbamates
Share to Clinical Trials as Topic
Share to Drug Combinations

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Interactions

Share to Heterocyclic Compounds, 4 or More Rings

Share to Ribavirin

Share to Sofosbuvir

Share to Sustained Virologic Response

Source

Identifiers

PMID: 28468532
DOI: 10.1080/17474124.2017.1326817

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Sofosbuvir and velpatasvir for the treatment of hepatitis C.PMID 28468532Read ↗

Sofosbuvir-velpatasvir: A single-tablet treatment for hepatitis C infection of all genotypes.Semantic proximity Read ↗

A pangenotypic, single tablet regimen of sofosbuvir/velpatasvir for the treatment of chronic hepatitis C infection.Semantic proximity Read ↗

Pharmacokinetic drug evaluation of velpatasvir plus sofosbuvir for the treatment of hepatitis C virus infection.Semantic proximity Read ↗

Sofosbuvir/velpatasvir regimen promises an effective pan-genotypic hepatitis C virus cure.Semantic proximity Read ↗

Sofosbuvir/Velpatasvir: The First Pangenotypic Direct-Acting Antiviral Combination for Hepatitis C.Semantic proximity Read ↗

Dual sofosbuvir and ribavirin therapy for chronic hepatitis C infection.Semantic proximity Read ↗

Sofosbuvir and Velpatasvir: A complete pan-genotypic treatment for HCV patients.Semantic proximity Read ↗

Key points for the management of hepatitis C in the era of pan-genotypic direct-acting antiviral therapySemantic proximity Read ↗

Safety and efficacy of sofosbuvir plus velpatasvir with or without ribavirin for chronic hepatitis C virus infection: A systematic review and meta-analysis.Semantic proximity Read ↗

Efficacy of the Combination of Sofosbuvir, Velpatasvir, and the NS3/4A Protease Inhibitor GS-9857 in Treatment-Naïve or Previously Treated Patients With Hepatitis C Virus Genotype 1 or 3 Infections.Semantic proximity Read ↗

Efficacy of Sofosbuvir, Velpatasvir, and GS-9857 in Patients With Genotype 1 Hepatitis C Virus Infection in an Open-Label, Phase 2 Trial.Semantic proximity Read ↗

Sofosbuvir/Velpatasvir (Epclusa) for Hepatitis C.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.